Merck & Co., Inc. MRK announced encouraging data Tuesday from a key study of patients with lung cancer. The combination of Merck's blockbuster drug Keytruda and two chemotherapy medicines helped patients live longer and played a role in stopping the disease from advancing.
The Analyst
SunTrust Robinson Humphrey's John Boris upgraded Merck's stock rating from Hold to Buy with a price target boosted from $54 to $72.
The Thesis
Merck was expected to report positive data, but the readout may have surprised investors, as it came "much earlier" than expected, Boris said in the upgrade note. (See the analyst's track record here.)
The "significantly longer [overall survival and progression-free survival]" readout should give the company the ability to sustain its first-mover advantage in the space, the analyst said.
The objective response rate in the Keytruda study was almost double that of chemotherapy alone, Boris said.
The median progression-free survival rate showed "a significant improvement," and about 75 percent of patients in the chemo segment who discontinued treatment then crossed over to the Keytruda and chemo combination, he said.
Price Action
Shares of Merck were trading higher by nearly 7 percent at the time of publication.
The Bull Thesis For Merck Is Evaporating
Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
